成纤维生长因子受体抑制剂化合物专利申请分析  

Patent application analysis of FGFR inhibitors

作　　者：赵冬梅[1] 杨秀岩 ZHAO Dong-mei;YANG Xiu-yan(Patent Examination Cooperation Jiangsu Center of the Patent Office,Suzhou 215000,China;Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]国家知识产权局专利局专利审查协作江苏中心,苏州215000 [2]上海交通大学医学院,上海200025

出　　处：《中国新药杂志》2020年第8期841-851,共11页Chinese Journal of New Drugs

基　　金：国家自然科学基金(21702137)。

摘　　要：本文分析了成纤维生长因子受体(FGFR)抑制剂的专利申请情况,对其专利申请趋势、全球专利申请人、国内专利申请人进行剖析,阐述了选择性FGFR抑制剂已逐渐成为全球尤其是国内的研发热点,总结相关重点申请人的化合物专利中公开的大量结构和活性的关系,进行构效分析,帮助研发人员进行合理药物设计,并对其知识产权策略的制定提供参考。Here we analyzed the data of patent applications of FGFR inhibitors including its development trends,global patent applicant,domestic patent applicant. Based on the results of the data analysis,research hotspots of selective FGFR inhibitors was clarified. Emphasis is put on the analysis of compound patents of key applicants in order to summarize the structure-activity relationship,offer help in rational drug design and provide reference for the formulation of intellectual property strategy.

关 键 词：FGFR抑制剂 专利分析 药物设计 

分 类 号：R95[医药卫生—药学]